Meditope Biosciences Inc.'s meditope-enabled linker technology could improve upon first-generation antibody-drug conjugates by producing ADCs that are more stable and homogeneous.

First-generation ADC technologies typically link cytotoxic agents to naturally occurring amino acids on mAbs, such as cysteine or lysine. Because any given mAb contains numerous cysteine and lysine sequences, conjugating the payload to a naturally occurring amino acid can result in a heterogeneous drug mixture. Some mAbs may have no cytotoxic drugs attached, while others in the same product may have six or more linked payloads.